These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19489219)

  • 1. [Molecular phenotypes of breast cancer and their clinical application].
    Tang P; Wei B; Hicks DG; Skinner K; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):13-7. PubMed ID: 19489219
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
    Voduc D; Nielsen TO
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
    Bershteĭn LM
    Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
    [No Abstract]   [Full Text] [Related]  

  • 5. Triple-negative breast cancer.
    Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
    [No Abstract]   [Full Text] [Related]  

  • 6. [Basal subtype of breast cancer--a unit of specific characteristics of immunophenotyping?].
    Niemiec J; Ryś J
    Pol J Pathol; 2011 Dec; 62(4 Suppl 4):s36-44. PubMed ID: 22693732
    [No Abstract]   [Full Text] [Related]  

  • 7. Few positives for triple-negative breast cancer.
    Hede K
    J Natl Cancer Inst; 2011 Apr; 103(7):532-3. PubMed ID: 21436063
    [No Abstract]   [Full Text] [Related]  

  • 8. [Gene expression analysis and its clinical use in breast tumors].
    Semiglazov VF; Semiglazov VV; Moiseenko FV; Bogdanov AA; Boĭtsov VV; Viaz'min SV; Gorab DN; Chubenko VA; Brezhnev NV; Luk'ianchikova VS; Dubina MV
    Vopr Onkol; 2013; 59(1):25-9. PubMed ID: 23805447
    [No Abstract]   [Full Text] [Related]  

  • 9. [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
    Zhang B
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):241-4. PubMed ID: 21575491
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of triple negative breast cancer.
    Oakman C; Viale G; Di Leo A
    Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.
    Āboliņš A; Vanags A; Trofimovičs G; Miklaševičs E; Gardovskis J; Štrumfa I
    Pol J Pathol; 2011; 62(1):65-8. PubMed ID: 21574108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
    Roukos DH
    J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
    [No Abstract]   [Full Text] [Related]  

  • 13. Estrogen, progesterone, and Her-2/neu receptor expression discrepancy in primary tumors and in-breast relapse in patients with breast cancer.
    Mavrova R; Radosa J; Schmitt K; Bohle RM; Rody A; Solomayer EF; Juhasz-Böess I
    Breast J; 2014; 20(3):322-4. PubMed ID: 24720257
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
    Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for early-stage breast cancer.
    McArthur HL; Hudis CA
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful endocrine therapy for locally advanced mucinous carcinoma of the breast.
    Nakagawa T; Sato K; Moriwaki M; Wada R; Arakawa A; Saito M; Kasumi F
    Breast J; 2012; 18(6):632-3. PubMed ID: 23110390
    [No Abstract]   [Full Text] [Related]  

  • 20. [Molecular subtypes and individualized treatment of breast cancer].
    Xu BH; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):641-4. PubMed ID: 21122374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.